AngioDynamics has launched an investigator-led pulmonary embolism research fund in collaboration with The PERT Consortium to support independent clinical studies, the company announced on Friday.
The ALPHA-PE Research Fund is designed to back physician-led research that improves understanding of thromboembolic disease and strengthens evidence across prevention, diagnosis, treatment and long-term management. The pulmonary embolism research fund aims to generate clinically relevant data that can directly inform real-world practice.
“Physician-led, investigator-driven research is essential to closing critical evidence gaps in pulmonary embolism care,” said National PERT Research Consortium Co-Chair Dr. Amir Darki. “The ALPHA-PE Research Fund represents a meaningful investment in supporting innovation, fostering collaboration, and advancing impactful research that will directly inform real-world practice and improve patient outcomes.”
Pulmonary embolism affects roughly one in every 1,000 Americans each year and contributes to more than 50,000 deaths annually. While blood thinners and anticoagulants remain the most common treatments, delayed diagnosis or inadequate management can make the condition life-threatening.
The PERT Consortium promotes multidisciplinary pulmonary embolism response teams to streamline diagnosis and treatment while improving patient outcomes. Its work focuses on advancing pulmonary embolism science through research and education for both healthcare professionals and the public.
The pulmonary embolism research fund is currently accepting proposals covering disease characterization, risk assessment and prevention, diagnostics, therapeutic pathways, patient outcomes, resource utilization and complex clinical settings. Grants ranging from $50,000 to $750,000 over one to three years will be awarded to selected investigators.
“This initiative reflects our commitment to supporting the cardiovascular community in closing critical data gaps in pulmonary embolism care,” said Laura Piccinini, senior vice president and general manager of Cardiovascular & International at AngioDynamics. “By supporting investigator-led studies, we strengthen the evidence base for approaches that can improve patient outcomes and advance the standard of care.”
